Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS
Status:
Not yet recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to see the associations of metabolic responses of metformin with
single nucleotide polymorphisms (SNPs) (rs628031 and rs2282143) of solute carrier family 22
member 1 (SLC22A1) gene in women with polycystic ovary syndrome (PCOS). This prospective
clinical study will be conducted in the department of Endocrinology, Bangabandhu Sheikh Mujib
Medical University (BSMMU) from February 2023 to September 2024 over a period of two years. A
total of at least 100 women with PCOS (18 - 35 years) diagnosed based on International
Evidence-based Guideline for PCOS 2018, will be included consecutively by convenient
sampling. After taking informed written consent, relevant clinical history will be taken and
physical examinations will be done at baseline. Following a run in phase of three weeks,
patients will visit thrice after 1, 12 & 24 weeks of metformin maintenance therapy with a
window period of 14 days both ways. Blood samples will be collected in fasting state at
baseline and after 24 weeks of treatment to measure glycemic status, lipid profile, fasting
insulin, c-peptide and detection of SLC22A1 gene (rs628031 and rs2282143) polymorphisms.
Glucose will be measured by glucose oxidase method, lipids by glycerol phosphate
dehydrogenase peroxidase method, insulin by chemiluminescent microparticle immunoassay,
c-peptide by enzyme-linked immunosorbent assay (ELISA) and genetic analysis of rs628031 and
rs2282143 by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Phase:
Phase 4
Details
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Collaborator:
Department of Genetic Engineering and Biotechnology, Dhaka University